ZyVersa Therapeutics Reports Full Year 2025 Financial Results

Biopharmaceutical company advancing pipeline of novel drugs for inflammatory and renal diseases

Mar. 31, 2026 at 9:19pm

Got story updates? Submit your updates here. ›

A polished glass beaker filled with a vibrant blue liquid, symbolizing the advanced pharmaceutical research and development at the heart of ZyVersa's business, set against a clean, monochromatic background with dramatic studio lighting and deep shadows.ZyVersa's pipeline of novel drug candidates aims to address significant unmet needs in inflammatory and kidney diseases.Lighthouse Point Today

ZyVersa Therapeutics, a clinical-stage specialty biopharmaceutical company, reported its full year 2025 financial results and provided a business update. The company is advancing a pipeline focused on inflammatory and renal diseases, with lead programs including Inflammasome ASC Inhibitor IC 100 and Cholesterol Efflux Mediator VAR 200.

Why it matters

ZyVersa's pipeline targets large unmet needs in inflammatory and renal diseases, with a total addressable market estimated over $100 billion. The company's two lead programs have the potential to provide new treatment options for patients suffering from these debilitating conditions.

The details

ZyVersa reported a net loss of $25 million for 2025, primarily due to a $18.6 million impairment charge for in-process R&D. The company reduced R&D expenses by 37% and G&A expenses by 22% compared to 2024. ZyVersa expects its current cash will only fund operations on a month-to-month basis, and plans to seek additional financing through public/private equity, debt, or other sources.

  • ZyVersa plans to file an IND for Inflammasome ASC Inhibitor IC 100 in Q4 2026 and initiate a Phase 1 trial in Q1 2027.
  • The company will initiate a Phase 2a trial for Cholesterol Efflux Mediator VAR 200 in patients with FSGS and Alport Syndrome in Q2 2026, with an interim readout expected around Q4 2026.

The players

ZyVersa Therapeutics, Inc.

A clinical-stage specialty biopharmaceutical company developing first-in-class drugs for inflammatory and renal diseases.

Stephen C. Glover

ZyVersa's Co-founder, Chairman, CEO, and President.

Got photos? Submit your photos here. ›

What they’re saying

“The next 18 months are poised to be transformative for ZyVersa.”

— Stephen C. Glover, Co-founder, Chairman, CEO, and President

What’s next

ZyVersa will seek additional financing through public or private equity, debt, or other sources to support its ongoing operations and clinical development programs.

The takeaway

ZyVersa is advancing a promising pipeline of novel drugs targeting large unmet needs in inflammatory and renal diseases, but will require additional capital to fund its ambitious clinical development plans over the next 18 months.